- Home
- AARD vs TVGN Comparison
AARD vs TVGN Comparison
Compare AARD & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- TVGN
- Stock Information
- Founded
- AARD 2017
- TVGN 2020
- Country
- AARD United States
- TVGN United States
- Employees
- AARD N/A
- TVGN N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- TVGN Blank Checks
- Sector
- AARD Health Care
- TVGN Finance
- Exchange
- AARD Nasdaq
- TVGN Nasdaq
- Market Cap
- AARD 186.3M
- TVGN 179.0M
- IPO Year
- AARD 2025
- TVGN N/A
- Fundamental
- Price
- AARD $14.83
- TVGN $0.70
- Analyst Decision
- AARD Strong Buy
- TVGN Strong Buy
- Analyst Count
- AARD 7
- TVGN 1
- Target Price
- AARD $31.43
- TVGN $10.00
- AVG Volume (30 Days)
- AARD 168.9K
- TVGN 552.0K
- Earning Date
- AARD 11-14-2025
- TVGN 11-18-2025
- Dividend Yield
- AARD N/A
- TVGN N/A
- EPS Growth
- AARD N/A
- TVGN N/A
- EPS
- AARD N/A
- TVGN N/A
- Revenue
- AARD N/A
- TVGN N/A
- Revenue This Year
- AARD N/A
- TVGN N/A
- Revenue Next Year
- AARD N/A
- TVGN N/A
- P/E Ratio
- AARD N/A
- TVGN N/A
- Revenue Growth
- AARD N/A
- TVGN N/A
- 52 Week Low
- AARD $4.88
- TVGN $0.64
- 52 Week High
- AARD $19.58
- TVGN $3.09
- Technical
- Relative Strength Index (RSI)
- AARD 57.81
- TVGN 37.42
- Support Level
- AARD $10.75
- TVGN $0.64
- Resistance Level
- AARD $17.94
- TVGN $0.74
- Average True Range (ATR)
- AARD 1.31
- TVGN 0.05
- MACD
- AARD -0.02
- TVGN 0.00
- Stochastic Oscillator
- AARD 48.48
- TVGN 27.84
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.